This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (PLANET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00885885
Recruitment Status : Completed
First Posted : April 22, 2009
Last Update Posted : August 1, 2017
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with FOLFOX 4 Chemotherapy or Panitumumab with FOLFIRI Chemotherapy in Subjects with Wild- Type KRAS Colorectal Cancer and liver-only Metastases.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: Panitumumab+FOLFOX-4 Drug: Panitumumab+FOLFIRI Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer and Liver-only Metastases.
Study Start Date : May 2009
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine

Drug Information available for: Panitumumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 1
Panitumumab+FOLFOX 4
 Drug: Panitumumab+FOLFOX-4

Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.

A cycle of panitumumab is defined as 14 days.

FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:

  • Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle
  • Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2
  • A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2
  • 5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2
Experimental: 2
Panitumumab+FOLFIRI
 Drug: Panitumumab+FOLFIRI

Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.

A cycle of panitumumab is defined as 14 days.

FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:

  • Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle
  • Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing
  • A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1
  • 5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Objective response rate [ Time Frame: 2009-2013 ]

Secondary Outcome Measures :
  1. % of patients whose disease becomes resectable [ Time Frame: 2009-2013 ]
  2. Time to resection [ Time Frame: 2009-2013 ]
  3. Duration of response [ Time Frame: 2009-2013 ]
  4. Progression-free survival [ Time Frame: 2009-2013 ]
  5. Time to treatment failure [ Time Frame: 2009-2013 ]
  6. Time to disease relapse following surgery. [ Time Frame: 2009-2013 ]
  7. Adverse Events [ Time Frame: 2009-2013 ]
  8. Evaluation of molecular predictive markers for response. [ Time Frame: 2009-2013 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Man or woman > 18 years < 75 of age
  • Competent to comprehend, sign, and date an IEC-approved informed consent form
  • Histologically confirmed adenocarcinoma of the colon or rectum
  • Wild Type KRAS status

  • Metastatic colorectal carcinoma exclusively affecting only the liver, compliant with one of the following criteria

    1. Number of liver metastasis ≥ 4.
    2. Size of one liver metastasis > 10 cm in diameter.
    3. Liver metastases technically not resectable.
  • At least 1 uni-dimensionally measurable lesion

  • Patients with the following characteristics will be included:

    1. Recurrence after adjuvant treatment with 5-fluorouracil/folinic acid or capecitabine +/- radiotherapy with a disease-free interval > than 6 months after its completion; or after oxaliplatin containing adjuvant treatment with a disease-free interval > than 12 months
    2. Recurrence after surgical treatment and/or radiotherapy with no adjuvant systemic treatment.
    3. De novo diagnosis of the disease.
  • Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior chemotherapy.
  • Prior radiotherapy is acceptable.
  • Patients deemed to have no major contra-indication to liver surgery from a general health perspective.
  • Karnofsky performance status ≥ 70%
  • Adequate bone marrow function: neutrophils ≥ 1.5 x109/ L; platelets ≥ 100 x109/ L;hemoglobin ≥ 9g/ dL
  • Hepatic and metabolic function as follows:

Total bilirubin count ≤ 1.5 x ULN and not increasing more than 25% within the last 4 weeks; ALAT and ASAT < 5 x ULN;

  • Renal function, calculated creatinine clearance or 24 hour creatinine clearance ≥ 50 mL/ min.
  • Magnesium > LLN

Exclusion Criteria:

  • Prior anti-EGFr antibody therapy (eg, cetuximab) or treatment small molecule EGFr tyrosine kinase inhibitors (eg, erlotinib).Subjects who have experienced an infusion reaction to their first dose of anti-EGFR therapy (cetuximab) may participate in this clinical trial.
  • Surgery (not including diagnostic biopsy) and/or radiotherapy in the 4 weeks prior to inclusion in the study.
  • Metastasis on any site other than the liver, including extrahepatic lymph nodes.
  • Prior malignant tumor in the last 5 years, except a history of basal cell carcinoma of the skin or pre-invasive carcinoma of the skin.
  • Systemic chemotherapy, hormonal therapy, immunotherapy or experimental or approved proteins/antibodies (eg, bevacizumab) ≤ 30 days before inclusion
  • Unresolved toxicities from prior systemic therapy that, in the opinion of the investigator, does not qualify the patient for inclusion
  • Significant cardiovascular disease including unstable angina or myocardial infarction within 6 months before initiating study treatment or a history of ventricular arrhythmia
  • History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest CT scan
  • Treatment for systemic infection within 14 days before initiating study treatment
  • Active inflammatory bowel disease or other bowel disease causing chronic diarrhoea (defined as > 4 loose stools per day)
  • History of Gilbert's syndrome or dihydropyrimidine deficiency
  • History of any medical condition that may increase the risks associated with study participation or may interfere with the interpretation of the study results
  • Known positive test for human immunodeficiency virus infection, hepatitis C virus, chronic active hepatitis B infection
  • subject allergic to the ingredients of the study medication or to Staphylococcus protein A
  • Any co-morbid disease that would increase risk of toxicity
  • Any kind of disorder that compromises the ability of the subject to give written informed consent and/or comply with the study procedures
  • Any investigational agent within 30 days before enrolment
  • Must not have had a major surgical procedure within 28 days of randomization
  • Subject who is pregnant or breast feeding
  • Woman or man of childbearing potential not consenting to use adequate contraceptive precautions i.e. double barrier contraceptive methods (eg diaphragm plus condom), or abstinence during the course of the study and for 6 months after the last study drug administration for women, and 1 month for men
  • Subject unwilling or unable to comply with study requirements
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885885


Locations
Layout table for location information
Spain
Spanish Cooperative Group for Gastrointestinal Tumour Therapy
Madrid, Spain, 28046
Sponsors and Collaborators
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Amgen
Investigators
Layout table for investigator information
Study Chair: Albert Abad, MD, phD ICO-H. Germans Trial i Pujol. Badalona. Spain
Study Chair: Alfredo Carrato, MD, phD Hospial Ramón y Cajal. Madrid. Spain
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
ClinicalTrials.gov Identifier: NCT00885885    
Other Study ID Numbers: TTD-08-04
EudraCT: 2008-006766-28
First Posted: April 22, 2009    Key Record Dates
Last Update Posted: August 1, 2017
Last Verified: July 2017
Keywords provided by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD):
Colorectal Cancer
Panitumumab
FOLFOX-4
FOLFIRI
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
 Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Panitumumab
Antineoplastic Agents, Immunological
Antineoplastic Agents